Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT07583342
PHASE4

Evaluating RELiZORB Use for the Treatment of Feeding Intolerance in Adults With Moderate to Severe Acute Pancreatitis

Sponsor: Northwell Health

View on ClinicalTrials.gov

Summary

The goal of this study is to learn if Relizorb, a fat-digesting enzyme, can improve tolerance of tube feeds in adult patients with moderate to severe pancreatitis. The main question it aims to answer is: Does Relizorb allow more nutrition to be delivered to participants than they received without it? Participants will be observed with standard, universal monitoring after adding Relizorb to their nutrition regimen.

Official title: Open-label, Multicenter, Phase IV, Study Evaluating RELiZORB Use for the Treatment of Feeding Intolerance in Adults With Moderate to Severe Acute Pancreatitis

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

15

Start Date

2025-12-08

Completion Date

2026-12

Last Updated

2026-05-13

Healthy Volunteers

No

Interventions

DEVICE

RELiZORB digestive enzyme (immobilized lipase) cartridge

An in-line digestive enzyme cartridge designed for hydrolyzing lipids within enteral nutrition will be used to improve tube feed tolerance in patients with moderate to severe pancreatitis.

Locations (5)

South Shore University Hospital

Bay Shore, New York, United States

North Shore University Hospital

Manhasset, New York, United States

Lenox Hill Hospital

Manhattan, New York, United States

Long Island Jewish Medical Center

New Hyde Park, New York, United States

Staten Island University Hospital

Staten Island, New York, United States